Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab
- PMID: 32591357
- DOI: 10.1136/annrheumdis-2020-218075
Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab
Keywords: B-Lymphocytes; arthritis, rheumatoid; rituximab.
Conflict of interest statement
Competing interests: None declared.
Comment in
-
Response to: 'Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab' by Schulze-Koops et al.Ann Rheum Dis. 2021 May;80(5):e68. doi: 10.1136/annrheumdis-2020-218148. Epub 2020 Jun 26. Ann Rheum Dis. 2021. PMID: 32591359 No abstract available.
Comment on
-
Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies.Ann Rheum Dis. 2020 May;79(5):667-668. doi: 10.1136/annrheumdis-2020-217424. Epub 2020 Apr 2. Ann Rheum Dis. 2020. PMID: 32241793 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical